Loqtorzi
Payments companies reported to CMS as associated with Loqtorzi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Loqtorzi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Loqtorzi
These are the largest totals companies reported as associated with Loqtorzi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Krzysztof Misiukiewicz | New York, NY | Medical Oncology | $46,309.34 |
| Chaitali Nangia | Costa Mesa, CA | Hematology & Oncology | $31,862.53 |
| Panayiotis Savvides | Phoenix, AZ | Hematology & Oncology | $31,687.20 |
| Shravan Kandula | Orlando, FL | Radiation Oncology | $19,923.18 |
| Zujun Li | New York, NY | Medical Oncology | $17,510.70 |
| Victoria Villaflor | Orange, CA | Medical Oncology | $16,365.12 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $14,370.93 |
| Tarek Mekhail | Orlando, FL | Hematology & Oncology | $13,918.49 |
| Daneng Li | Duarte, CA | Medical Oncology | $13,793.63 |
| Kyaw Thein | Las Vegas, NV | Hematology (Internal Medicine) | $13,075.05 |
Prescribed Loqtorzi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.